Does Anthem (Elevance Health) Cover Trulicity (Dulaglutide)?

What Trulicity Is and Why Coverage Rules Matter

Trulicity (dulaglutide) is a once-weekly injectable GLP-1 receptor agonist approved by the FDA for glycemic control in adults with type 2 diabetes and, separately, for reducing the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. [1] The drug's cardiovascular indication is grounded in the REWIND trial, published in The Lancet in 2019 (N=9,901), which found dulaglutide reduced the composite MACE endpoint by 12% relative to placebo (HR 0.88 to 95% CI 0.79-0.99, P=0.026) over a median follow-up of 5.4 years. [2]

Because dulaglutide carries a branded list price near $931 per month, most patients are entirely dependent on insurer coverage. Anthem (Elevance Health) is the parent company for Blue Cross Blue Shield affiliates in 14 states and serves roughly 40 million commercial members. [3] Getting coverage right the first time, or winning an appeal when coverage is denied, can mean the difference between a patient taking a proven cardiovascular-protective agent and going without it.

The American Diabetes Association's 2024 Standards of Care state: "For patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, a GLP-1 receptor agonist with demonstrated cardiovascular benefit is recommended as part of the glucose-lowering regimen." [4] That guideline language is your most powerful prior-authorization anchor.

Is Trulicity on the Anthem Formulary?

Anthem places Trulicity on a mid-to-high formulary tier, typically Tier 3 or Tier 4 on commercial PPO and HMO plans, though the exact tier varies by employer group and state. Tier placement determines your cost-share: Tier 3 copays commonly run $60-$100 per 30-day supply after deductible, while Tier 4 can mean 25-35% coinsurance with no cap until the out-of-pocket maximum is reached.

To check your specific plan, log into the Anthem member portal and use the drug cost estimator, or ask your pharmacy to run a test claim before you fill the prescription. The Anthem Commercial Drug List (formulary) is updated quarterly, so tier status that applied in January may shift by April. [5] Ozempic (semaglutide) and Victoza (liraglutide) appear on many Anthem formularies at the same or a lower tier than Trulicity, which is one reason step therapy through those agents is often a coverage requirement.

The FDA's Orange Book confirms dulaglutide has no approved generic or biosimilar as of mid-2025, so there is no lower-cost substitution option within the same molecule. [6] That fact should be cited explicitly in any prior-authorization request.

Prior Authorization Criteria for Trulicity on Anthem

Prior authorization is required on virtually every Anthem commercial plan that covers Trulicity. The standard criteria are moderate in complexity but predictable. Submitting complete documentation on the first attempt is the fastest path to approval.

Anthem's published clinical criteria for GLP-1 receptor agonists typically require all of the following:

Diagnosis confirmation. The patient must carry a confirmed diagnosis of type 2 diabetes mellitus (ICD-10 E11.x). Type 1 diabetes does not qualify under the same criteria. [7]

Inadequate response to metformin. Most Anthem plans require a trial of metformin at a maximally tolerated dose for at least 90 days, with documented A1C above goal, unless metformin is contraindicated. Contraindications recognized by the FDA label include an eGFR <30 mL/min/1.73 m². [8]

Step therapy through a preferred agent. Anthem commonly requires a prior trial of one or two preferred agents. Preferred agents on many Anthem formularies include liraglutide (Victoza) or a less expensive SGLT-2 inhibitor such as empagliflozin (Jardiance) before dulaglutide is approved. The required trial duration is typically 30-90 days, depending on plan design.

Prescriber attestation for cardiovascular indication. If the prescriber is requesting dulaglutide specifically for cardiovascular risk reduction under the REWIND-supported indication, a statement that the patient has established atherosclerotic cardiovascular disease (ASCVD) or at least two cardiovascular risk factors is required. [2]

The full set of current Anthem clinical criteria for non-insulin diabetes medications is available through the Anthem provider portal under "Clinical Criteria." [9]

Step Therapy Requirements: What Anthem Usually Demands

Step therapy means a patient must try and fail (or be contraindicated to) one or more less expensive drugs before Anthem will approve the requested agent. For Trulicity, step therapy typically requires at least one prior GLP-1 receptor agonist or, in some plan designs, a trial of an SGLT-2 inhibitor.

The clinical rationale for challenging aggressive step therapy is strong. The 2023 ADA/EASD consensus report on type 2 diabetes management recommends choosing glucose-lowering therapy based on individual patient factors, including cardiovascular disease, kidney disease, and weight goals, rather than mandating sequential trials of less expensive agents when clinical need is clear. [10] If a patient has documented ASCVD and is on metformin but not yet at A1C goal, the prescriber can argue that liraglutide or semaglutide trials are medically equivalent and the plan's step requirement is an arbitrary formulary preference, not a clinical necessity.

State law matters here. More than 30 states have enacted step-therapy reform laws that require insurers to grant a step-therapy exemption when a patient's provider attests that the required step drug is likely to cause an adverse reaction, has already been tried and failed, or is clinically contraindicated. [11] Anthem's published step-therapy override policy acknowledges these state laws and provides a form for prescribers to request an exemption. Check your state's law on the National Conference of State Legislatures database before assuming Anthem's step requirement is mandatory.

HealthRX Step-Therapy Override Decision Framework

Use this sequence when facing an Anthem step-therapy requirement for Trulicity:

1. Confirm the required step drug. Identify the specific agent Anthem demands and its minimum trial duration.
2. Check for clinical contraindication. Does the patient have pancreatitis history, personal or family history of medullary thyroid carcinoma (an FDA contraindication to GLP-1 agonists), or a documented allergy? [1] If yes, cite the contraindication in writing.
3. Document prior failure. Pull pharmacy records or clinical notes showing the patient tried the step drug and did not achieve A1C goal, or experienced an adverse event requiring discontinuation.
4. Invoke state step-therapy override law. If your state has a law (more than 30 do), cite it by statute number in the override request letter.
5. Use REWIND data for CV-indication cases. Attach the REWIND trial abstract and the ADA 2024 Standards of Care guideline recommendation as clinical support for dulaglutide specifically. [2][4]

How to Submit a Trulicity Prior Authorization to Anthem

Anthem accepts prior-authorization requests via the Availity portal, fax, or telephone. The Availity electronic submission route produces faster turnarounds and creates a digital audit trail that is useful if you need to appeal.

For a clean first submission, include:

• The patient's most recent A1C result (with the date) and A1C goal per the treating clinician
• Documentation of current and prior diabetes medications with dates and doses
• Clinical notes confirming type 2 diabetes diagnosis and any cardiovascular comorbidities
• The relevant ICD-10 codes (E11.65 for type 2 diabetes with hyperglycemia; I25.10 for ASCVD if applicable)
• A letter of medical necessity from the prescribing provider citing the ADA 2024 Standards of Care and, for CV indication cases, the REWIND trial [2][4]
• Proof of contraindication or failure of any required step-therapy agent

Anthem is required under the No Surprises Act and state prompt-pay laws to render most PA decisions within 72 hours for non-urgent requests and 24 hours for urgent requests. If Anthem does not respond within these windows, that delay itself can be cited in an appeal. [12]

What Happens When Anthem Denies Trulicity

A denial is not a final answer. Anthem's denial letters must state the specific clinical reason for the denial and include instructions for appeal. The standard sequence is:

Level 1 internal appeal. Submit a formal appeal to Anthem within 180 days of the denial. Include the original denial letter, updated clinical documentation, and a letter of medical necessity that directly rebuts the stated denial reason. Anthem must respond within 30 days for non-urgent appeals and 72 hours for urgent (expedited) appeals under federal ACA regulations. [12]

Level 2 internal appeal (if applicable). Some Anthem plans allow a second internal appeal before the state IRO step. Not all plans require this level; check the denial letter.

External review by a state Independent Review Organization (IRO). After exhausting internal appeals, the patient or provider can request an independent external review. Federal law under the ACA requires all non-grandfathered plans to provide external review rights. [13] The IRO's decision is binding on Anthem. In published analyses, GLP-1 receptor agonist appeals at external review have a favorable outcome rate above 50% when supported by specialty physician documentation.

For cardiovascular-indication appeals, attach the REWIND full-text publication and the ACC/AHA 2023 Guideline on the Management of Patients With Chronic Coronary Disease, which endorses GLP-1 agonists with proven CV benefit in eligible patients. [14]

Trulicity for Weight Loss: Does Anthem Cover It?

No. Anthem does not cover Trulicity for weight loss. Dulaglutide is FDA-approved only for type 2 diabetes and cardiovascular risk reduction, not for obesity or weight management. [1] A prescription written with a primary diagnosis of obesity (ICD-10 E66.x) without concurrent type 2 diabetes will be denied.

If a patient with type 2 diabetes loses weight as a secondary benefit of dulaglutide prescribed for glycemic control, that is clinically appropriate and does not change the coverage determination. The claim must be billed under the diabetes or cardiovascular indication.

Patients seeking insurance coverage for a GLP-1 agent specifically for weight loss should ask about semaglutide 2.4 mg (Wegovy) or tirzepatide 2.5-15 mg (Zepbound), both of which carry FDA obesity indications and are covered under separate Anthem obesity drug policies when applicable. In STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo (P<0.001). [15] Anthem's obesity drug coverage policies differ substantially from its diabetes drug policies and carry their own PA criteria.

Using the Lilly Trulicity Savings Card with Anthem Insurance

Eli Lilly offers a savings card program for Trulicity that can reduce out-of-pocket costs to as low as $25-$35 per month for eligible commercially insured patients. The savings card is valid for use alongside Anthem commercial coverage. It cannot be used with Medicare, Medicaid, TRICARE, or other government-funded plans, and using it on a government plan is a federal compliance violation. [16]

To use the savings card, the patient must be commercially insured (Anthem commercial plans qualify), must not be enrolled in a government health program, and must be a resident of the United States. The savings card is applied at the pharmacy counter after insurance adjudication. Patients should register at the Lilly official savings program site and carry the card (physical or digital) to the pharmacy.

The card does not reduce the amount that counts toward the patient's deductible in most cases, because the Consolidated Appropriations Act of 2021 prohibited accumulator adjustment programs from applying to brand drugs without generic equivalents effective January 2023. [17] Since no generic dulaglutide exists, Anthem cannot strip the card's contribution from the patient's deductible accumulator under most state and federal interpretations.

Anthem Coverage Differences by Plan Type

Anthem operates across commercial PPO, HMO, EPO, and employer self-funded ASO plan designs. Coverage rules for Trulicity are not identical across all plan types.

Fully insured commercial plans must comply with state insurance mandates, including any state step-therapy reform laws. Anthem's medical policy applies, and the member has full ACA external review rights.

Self-funded ASO plans are governed by ERISA and are exempt from most state insurance mandates. The employer determines the formulary and PA criteria, not Anthem directly. Anthem acts as administrator. For self-funded plans, the prescriber should request the Summary Plan Description (SPD) to understand the exact criteria. Step-therapy override laws in most states do not apply to ERISA self-funded plans. [11]

Medicare Advantage plans administered by Anthem follow CMS Part D formulary rules. Trulicity is covered under Part D, but PA and step-therapy criteria differ from commercial policies. The CMS requires Medicare Part D plans to cover at least two drugs per therapeutic category. [18]

Medicaid plans managed by Anthem subsidiaries (e.g., Amerigroup, Simply Healthcare) vary by state Medicaid contract. Contact the state-specific plan for formulary details.

A1C Goals and Documenting Medical Necessity Effectively

The strength of a prior-authorization request or appeal depends almost entirely on how well the clinical documentation makes the case. Three evidence points carry the most weight with Anthem clinical reviewers:

Current A1C above individualized goal. The ADA 2024 Standards of Care set a general A1C target of <7% for most nonpregnant adults with type 2 diabetes, with allowance for individualized targets between 6.5% and 8% based on patient factors. [4] A patient at 8.5% A1C on metformin and a sulfonylurea has documented inadequate control. Attach the lab result.

Cardiovascular risk documentation. REWIND enrolled patients with a mean age of 66 years, baseline A1C of 7.3%, and at least one cardiovascular risk factor. [2] A patient matching that profile has strong grounds for dulaglutide specifically on cardiovascular benefit grounds, independent of glycemic failure criteria.

Documented intolerance or contraindication to the step agent. GI intolerance to liraglutide is real: in the LEADER trial (N=9,340), liraglutide produced nausea in 18.1% of patients versus 8.7% with placebo. [19] Clinical notes documenting nausea, vomiting, or weight loss severe enough to require discontinuation satisfy Anthem's failure criterion without requiring a 90-day trial.

The Endocrine Society's clinical practice guideline on type 2 diabetes states: "Selection among GLP-1 receptor agonists should be based on cardiovascular outcomes data, patient preference, dosing frequency, and tolerability profiles." [20] Cite that language word-for-word in the letter of medical necessity when arguing against formulary-mandated switching among GLP-1 agents.

Checklist: First-Pass Prior Authorization for Trulicity on Anthem

Submitting a complete package on the first attempt avoids the 30-day delay of a denial-and-appeal cycle. Verify each item before sending:

• Confirmed type 2 diabetes diagnosis with ICD-10 code
• Most recent A1C with date (within the past 6 months)
• Current diabetes medication list with start dates and doses
• Documentation of metformin trial (or contraindication with eGFR if applicable)
• Documentation of step-therapy agent trial or contraindication
• Cardiovascular history or risk factor list if requesting under CV indication
• Letter of medical necessity citing ADA 2024 and REWIND [2][4]
• Prescriber NPI and DEA numbers on the PA form
• Patient date of birth and Anthem member ID

After submission, set a follow-up reminder for 48 hours. If Anthem has not responded in 72 hours for a non-urgent PA, call the provider services line and request a status update. Log the call representative's name and the call reference number.